Please ensure Javascript is enabled for purposes of website accessibility

Vertex Pharmaceuticals Scores an Important Win

By Todd Campbell - Feb 16, 2018 at 8:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's 2018 financial outlook just got a bit better.

Rapidly growing sales for its two cystic fibrosis drugs led to Vertex Pharmaceuticals (VRTX 1.96%) being a top stock last year, and management hopes the FDA's sooner-than-expected approval of its third cystic fibrosis drug will keep the momentum going. The approval of Symdeko further expands Vertex Pharmaceuticals' dominance in treating this devastating disease, and that should provide plenty of support to the company's sales this year. 

Expanding its reach

There's no cure for cystic fibrosis, but Vertex Pharmaceuticals may help patients live longer. It won FDA approval of Kalydeco, its first cystic fibrosis drug, in 2013, and it secured FDA approval of a second drug, Orkambi, in 2015. Initially, these drugs won the FDA's green light in older patients; however, their labels have steadily expanded to include use in younger patients since then.

A megaphone shooting individual letters of the alphabet out of it.

IMAGE SOURCE: GETTY IMAGES.

The ability to treat increasingly younger patients has expanded Vertex Pharmaceuticals' addressable market to over 30,000 patients; however, tens of thousands of patients still aren't eligible to take Kalydeco and Orkambi, and that means there's still a big need for new treatments. 

On Tuesday, the FDA approved Vertex Pharmaceuticals' third drug, Symdeko, a combination of Kalydeco and a new drug, tezacaftor. The approval is important because Symdeko can be used by patients who can't take Orkambi because of side effects.

Unlike Orkambi, Symdeko's prescribing label doesn't warn about respiratory issues or require regular blood pressure monitoring. According to Geoffrey Porges, an analyst at Leerink Partners, Orkambi's drawbacks have limited its penetration to less than 60% of its addressable market. Since Symdeko offers a better safety profile than Orkambi, and Orkambi's sales were $1.3 billion last year, Symdeko's approval is a win for the company and, more importantly, patients.

Big money at stake

Some of Symdeko's sales will come at Orkambi's expense. However, Vertex Pharmaceuticals estimates its three drugs can address the needs of between 31,000 to 44,000 cystic fibrosis patients, up from fewer than 31,000 previously. Because these drugs are expensive (Symdeko's wholesale acquisition price is $292,000), every additional patient represents meaningful revenue for the company. After Symdeko's approval, Vertex Pharmaceuticals issued guidance for sales of between $2.65 billion to $2.8 billion in 2018, up from $2.17 billion in 2017 and roughly $1.7 billion in 2016.

Management's guidance could be conservative given its recent track record of over-delivering, but even if it isn't, the forecast should give the company significant operating leverage this year. The company didn't issue an earnings forecast for the year, but the average estimate by analysts is for EPS of $3.05 in 2018, up from $1.95 in 2017, and $0.85 in 2016.

The extra profitability will come in handy because it will provide important financial flexibility in support of phase 3 trials for two triplet combination therapies that are slated to begin soon. If those trials succeed, it could allow Vertex Pharmaceuticals to help as many as 68,000 of the 75,000 people with cystic fibrosis. That would be game-changing for patients and investors.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
VRTX
$287.32 (1.96%) $5.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.